Tirzepatide normalizes diabetic kidney disease through PI3K/AKT antioxidant signaling at 1/3 semaglutide dose | Research

The takeaway

Tirzepatide at 1/3 the dose of semaglutide equally reduced kidney injury markers and oxidative stress in diabetic nephropathy mice, working through PI3K/AKT pathway activation that was reversed by PI3K inhibition.

Insulin fails where tirzepatide succeeds
Tirzepatide at 1/3 dose restored kidney proteinuria markers where insulin treatment could not—through PI3K/AKT antioxidant signaling

What the researchers found

Tirzepatide 1/3 dose = semaglutide for: ↓glucose, ↓weight, ↓UACR. Insulin: could not restore UACR. RNA-seq: PI3K-AKT enriched. Tirzepatide: regulated oxidative stress via PI3K-AKT in podocytes. PI3K inhibitor: reversed antioxidative effect. DN treatment advantage over insulin.

Why it matters

Diabetic nephropathy leads to dialysis for millions. Tirzepatide achieving equal kidney protection at lower dose—where insulin fails for proteinuria—positions dual agonism as a superior approach for diabetic kidney disease.

How the study worked

DN mouse model. Tirzepatide, semaglutide, insulin comparison. RNA-seq of renal tissue. Mouse podocyte cell-5 (MPC5) high glucose experiments. PI3K inhibitor validation.

What this study cannot tell us

Mouse model. RNA-seq pathway enrichment is associative. Single PI3K inhibitor used. Short treatment duration. Podocyte cells may not represent all kidney cell types.

How to read the evidence

Preclinical with RNA-seq mechanism discovery and pharmacological validation. Good mechanistic study.

When this study was published

Published in 2025.

The bigger picture

The finding that insulin cannot restore proteinuria while GLP-1/GIP drugs can highlights that incretin-based kidney protection goes beyond glucose control—these drugs have direct renoprotective mechanisms.

Questions still open

Is the PI3K-AKT mechanism unique to tirzepatide or shared with semaglutide?
Should tirzepatide replace insulin for DN management?
Would combining tirzepatide with direct PI3K activators enhance renoprotection?

Common questions

Can tirzepatide protect kidneys better than insulin?

In this study, yes. While insulin controlled blood sugar in diabetic mice, it failed to reduce protein leaking into urine (proteinuria)—a key marker of kidney damage. Tirzepatide at one-third the dose of semaglutide successfully reduced proteinuria through a specific antioxidant pathway (PI3K/AKT).

Why does tirzepatide work at a lower dose?

Tirzepatide activates both GLP-1 and GIP receptors. This dual stimulation apparently provides more efficient kidney protection—achieving the same results as semaglutide (which only activates GLP-1) at one-third the dose. The PI3K/AKT antioxidant pathway appears to be more strongly activated by dual agonism.

Read the original research

GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.

International immunopharmacology, 146, 113877

View on PubMed ↗Publisher’s paper ↗

Citation

Tian, Yan; Tian, Ruixue; Juan, He; Guo, Yafan; Yan, Pan; Cheng, Yao; Li, Rongshan; Wang, Baodong. (2025). GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.. International immunopharmacology, 146, 113877. https://doi.org/10.1016/j.intimp.2024.113877